This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
BMS gets rights to anti-fibrotic small molecules from Calibr
22 Sep 2017
Bristol-Myers Squibb Co. received exclusive global development, manufacturing, and commercialization rights to preclinical small-molecule fibrotic therapeutics from California Institute for Biomedical Research (Calibr). The partners also established a fibrotic disease research collaboration.
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?